laboratoire spécialiste du traitement des maladies neurologiques rares

« Une technologie de rupture déclinable dans de nombreuses pathologies neurologiques »

> Communiqués de presse 2016

Inclusion of the first patient in the phase II clinical study that aims to test THN102 in patients affected by narcolepsy
Télécharger le PDF (260 Ko)

Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy
Télécharger le PDF (428 Ko)

Theranexus and its partners receive support from the FUI (French Inter-ministry Fund) for their project, Cx-COG
Télécharger le PDF (149 Ko)

Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)
Télécharger le PDF (174 Ko)

Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102
Télécharger le PDF (111 Ko)